[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367777-105":59,"doc-detail-367777-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","aav-for-ovarian-cancer-gene-therapy-review-article","AAV for ovarian cancer gene therapy - Review article","","A review article examines recent advancements in ovarian cancer treatment and addresses persistent relapse despite improved recurrence-free intervals from therapies such as PARP inhibitors, especially in BRCA-mutated or HRD cases. It evaluates adeno-associated virus (AAV) vectors for gene therapy by organizing strategies by target cells and target genes. Approaches include anti-angiogenesis and immune modulation, with emphasis on gene supplementation. New AAV capsid engineering enables targeted delivery to ovarian cancer stem cells identified by specific markers, while DNA sequencing technologies support precise therapeutic gene selection and incorporation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aav-for-ovarian-cancer-gene-therapy-review-article/367777/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aav-for-ovarian-cancer-gene-therapy-review-article/367777.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does ovarian cancer remain difficult to treat despite effective initial responses?","Question",{"text":113,"@type":114},"Most patients initially respond to platinum-based chemotherapy and cytoreductive surgery, but recurrence rates are nearly 80% in advanced cases. Recurrences show progressively shorter progression-free intervals and limited effectiveness after relapse, leading to poor long-term survival.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What gene therapy approaches does the review describe?",{"text":118,"@type":114},"The review summarizes gene therapy methods including gene silencing of oncogenes, gene restoration of mutated tumor suppressors, and gene supplementation by providing therapeutic genes to target cells.",{"name":120,"@type":111,"acceptedAnswer":121},"What role does AAV play in ovarian cancer gene therapy according to the article?",{"text":122,"@type":114},"AAV vectors are discussed as tools for gene therapy, supported by the ability to engineer the AAV capsid to achieve tissue tropism and targeted delivery. The article highlights strategies focused on ovarian cancer stem cells using capsid design and sequencing-supported therapeutic gene incorporation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367777,1790773964,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Gene [Therapy](Therapy www.nature.com/cgt)[ www.nature.com/cgt](Therapy www.nature.com/cgt)  \nREVIEW ARTICLE OPEN   \nAAV for ovarian cancer gene therapy  \nHee Chan Yoo 1,2 ✉ , Sangkil Lee1,2, Joong Yull Park 2,3 and Eun-Ju Lee2,4  \n© The Author(s) 2025  \n\n|  | Recent advancements in ovarian cancer treatment, particularly with PARP inhibitors, have markedly enhanced the recurrence-free interval, shifting the treatment paradigm and increasing treatment success in patients with BRCA mutations or HRD (homologous recombination deﬁciency) . However, a signiﬁcant proportion of cases experience relapse, resulting in poorer long-term survival rates when compared to other female cancers, such as breast cancer. This review explores the potential of adeno-associated virus (AAV) vectors for gene therapy in ovarian cancer and examines rational gene therapy strategies by categorizing them based on target cells and target genes to determine the most effective approach for ovarian cancer treatment. Speciﬁcally, it examines strategies such as anti-angiogenesis and immune modulation, highlighting the strategy of gene supplementation to hinder ovarian cancer progression. Innovations in AAV capsid design now allow for targeted delivery, focusing on ovarian cancer stem cells (CSCs) identiﬁed by speciﬁc markers. Additionally, leveraging DNA sequencing technologies enhances the identiﬁcation and incorporation |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| of therapeutic genes into AAV vectors, promising new avenues for ovarian cancer gene therapy. |  |  |\n|  | Cancer Gene Therapy (2025) 32:817–830; [https://doi.org/10.1038/s41417-025-00926-4](https://doi.org/10.1038/s41417-025-00926-4) |  |\n|  |  |  |\n\nINTRODUCTION  \nGlobally, ovarian cancer is the eighth most common cancer in women, accounting for an estimated 3.7% of cases and 4.7% of cancer deaths in 2020 [1] . It is the leading cause of gynecological cancer-related deaths and the second most common gynecologic cancer [2] . Over 90% of ovarian cancers are epithelial ovarian cancers (EOC), with high-grade serous ovarian cancer (HGSOC) being the predominant subtype [3] (Hereafter, these will be referred to as ovarian cancer) . Most ovarian cancers (75%) are diagnosed at an advanced stage (III or IV) and initially respond well to standard treatment (platinum-based chemotherapy and cytoreductive surgery) with a response rate of over 80% [4] . However, the recurrence rate is nearly 80% of advanced ovarian cancers, with progressively shorter progression-free intervals and repeated chemotherapy cycles [5] . Consequently, the 5-year survival rate is 26% for stage III and 14% for stage IV [6](Fig. 1a) . Treatment following recurrence is primarily ineffective, with a median survival time of only 2 years, making this disease essentially lethal [7] .  \nGene therapy encompasses the delivery of genes (DNA or RNA) to patients, aiming to inhibit the expression of oncogenes (gene silencing), restore mutated-tumor suppressor genes with normal genes (gene restoration), provide therapeutic genes to target cells (gene supplementation) [8] . Initially, research primarily concentrated on treating hereditary diseases with well-deﬁned causes. However, current investigations have expanded to include a variety of diseases, such as neurodegenerative diseases [9], rheumatoid arthritis [10], cardiovascular diseases [11], infectious diseases [12], and aging-related diseases [13] . Moreover, the expanded understanding of genes implicated in cancer formation, growth, and metastasis has stimulated research [14] and clinical  \ninvestigations [15] into cancer gene therapy, leading to notable advancements in the ﬁeld.  \nFor cancer gene therapy, two distinct groups of delivery vehicles exist viral and non-viral vectors. While both vectors have their advantages and limitations, the central challenge of vectors for cancer gene therapy is achieving efﬁcient and sa","cbCaiqXtI4YPubKX","https://ap.wps.com/l/cbCaiqXtI4YPubKX","pdf",2850052,14,"English","# Introduction\n## Ovarian cancer burden and treatment challenges\n## Concepts of cancer gene therapy and delivery vectors\n## Viral vectors and rationale for AAV","[{\"question\":\"Why does ovarian cancer remain difficult to treat despite effective initial responses?\",\"answer\":\"Most patients initially respond to platinum-based chemotherapy and cytoreductive surgery, but recurrence rates are nearly 80% in advanced cases. Recurrences show progressively shorter progression-free intervals and limited effectiveness after relapse, leading to poor long-term survival.\"},{\"question\":\"What gene therapy approaches does the review describe?\",\"answer\":\"The review summarizes gene therapy methods including gene silencing of oncogenes, gene restoration of mutated tumor suppressors, and gene supplementation by providing therapeutic genes to target cells.\"},{\"question\":\"What role does AAV play in ovarian cancer gene therapy according to the article?\",\"answer\":\"AAV vectors are discussed as tools for gene therapy, supported by the ability to engineer the AAV capsid to achieve tissue tropism and targeted delivery. The article highlights strategies focused on ovarian cancer stem cells using capsid design and sequencing-supported therapeutic gene incorporation.\"}]","AAV for ovarian cancer gene therapy - Review article | PDF",1790172554,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d85250a7fc1de49d6605bf863d2eb16e.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7ecf2a8f8dfa9bc64f671b2fd6597c6.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdabe5b5915c4b1f7caae8738a177e23.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f035c98fe85c758eecce60bb32d71e48.webp",980,1301]